Electroconvulsive therapy improves clinical manifestations of XXXX without changing serum @entity2252 levels.

@entity1 @entity13217 @entity308 @entity2252
UNASSIGNED: Electroconvulsive therapy (ECT) is effective in @entity13217 ( @entity13217 ). It may act through intracellular process modulation, but its exact mechanism is still unknown. Animal research supports a neurotrophic effect for ECT. We aimed to investigate the association between changes in serum @entity2252 (sBDNF) levels and clinical improvement following ECT in @entity1 with @entity13217 . Twenty-one @entity1 with @entity13217 (2 @entity1 , 19 @entity1 ; mean age, 63.5 years; S.D., 11.9) were assessed through the @entity308 ( @entity308 ), the Brief Psychiatric Rating Scale (BPRS), and the Clinical Global Impressions scale, Severity (CGIs) before and after a complete ECT cycle. At the same time-points, @entity1 underwent blood withdrawal for measuring sBDNF levels. ECT significantly reduced @entity308 , BPRS, and CGIS scores, but not sBDNF levels. No significant correlation was found between sBDNF changes, and each of @entity308 , BPRS, and CGIs score changes. sBDNF levels in @entity13217 @entity1 were low both at baseline and post-ECT. Our results do not support that improvements in @entity13217 following ECT are mediated through increases in sBDNF levels.
